サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1758897

アテローム性動脈硬化治療の世界市場

Atherosclerosis Therapeutics

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.02円
アテローム性動脈硬化治療の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アテローム性動脈硬化治療の世界市場は2030年までに137億米ドルに達する見込み

2024年に111億米ドルと推定されるアテローム性動脈硬化治療の世界市場は、分析期間2024-2030年にCAGR 3.5%で成長し、2030年には137億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるアテローム性動脈硬化症低分子は、CAGR 4.3%を記録し、分析期間終了までに92億米ドルに達すると予測されます。アテローム性動脈硬化症生物製剤セグメントの成長率は、分析期間中CAGR 2.0%と推定されます。

米国市場は30億米ドルと推定、中国はCAGR 6.7%で成長予測

米国のアテローム性動脈硬化治療市場は、2024年に30億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに28億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.8%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界のアテローム性動脈硬化治療市場- 主要動向と促進要因まとめ

アテローム性動脈硬化症は、医療の進歩にもかかわらず、なぜ依然として世界の健康危機なのか？

動脈壁にプラークが進行性に蓄積することを特徴とするアテローム性動脈硬化症は、依然として世界の心血管疾患の主要な要因の1つです。数十年にわたる研究と効果的な治療介入が可能であるにもかかわらず、心臓発作、脳卒中、末梢動脈疾患により毎年数百万人の命が奪われ続けています。このような持続的な有病率は、不健康な食事、座りがちな生活、喫煙、ストレスレベルの増加などの生活習慣がプラーク形成のリスクを高めていることが一因です。さらに、アテローム性動脈硬化症は、急性心血管系イベントとして顕在化する前に数十年にわたって静かに進行することが多く、早期発見と介入を特に困難にしています。世界化によって西洋的な食習慣が導入され、都市化によって身体活動が低下するにつれて、高所得国および発展途上国の人口はますます影響を受けています。この問題をさらに深刻にしているのは、糖尿病、高血圧、肥満などの合併症の増加であり、これらはすべて動脈硬化の進行を促進する重大な因子です。さらに、人口動態の変化、特に高齢化人口の世界の増加により、動脈硬化に関連した合併症の危険にさらされている、あるいはすでに罹患している患者が増加しています。スタチンやその他の脂質低下薬はコレステロール値の管理に有効であることが証明されているが、特定の高リスク集団に対しては十分に利用されていないか、あるいは不十分であることが多いです。また、患者のアドヒアランス、ヘルスケアへのアクセスの制限、無症候性進行も効果的な疾患管理を妨げています。これらの多面的な課題は、アテローム性動脈硬化症が依然として世界の健康上の緊急課題である理由を強調し、より洗練され、利用しやすく、個別化された治療アプローチの必要性を浮き彫りにしています。

イノベーションは動脈硬化治療の情勢をどのように変えているのか？

アテローム性動脈硬化症の治療法は、バイオテクノロジー、精密医療、分子生物学的研究の進歩に後押しされ、大きな変貌を遂げつつあります。スタチンや抗血小板薬などの伝統的な治療法は、依然として治療の礎となっています。しかし、脂質管理にとどまらず、プラークの蓄積を引き起こしている根本的な炎症や免疫の経路に対処する新しいアプローチが出現しつつあります。PCSK9阻害剤のようなモノクローナル抗体は、脂質低下療法の新時代をもたらし、従来の薬剤では達成不可能であったコレステロール低下を達成することができます。これらの生物学的製剤は、家族性高コレステロール血症の患者やスタチン不耐性の患者に特に有用です。CRISPRを含む遺伝子編集技術もまた、脂質代謝に関連する遺伝子を改変するために研究されており、動脈硬化を長期的に予防できる可能性があります。もう一つの成長分野はRNAベースの治療薬で、脂質合成や炎症に関与する特定の遺伝子標的を沈黙させることができます。血管内超音波や光干渉断層計などの画像技術は，プラークの特性をモニターし，治療反応をリアルタイムで評価するために，現在では治療戦略と統合されつつあります。薬剤溶出ステントや血管スカフォールドは安全性と有効性の両面で進化しており，全身的な薬物療法を補完する局所療法を提供しています。さらに、デジタルヘルスツールやウェアラブルデバイスの使用により、継続的な心血管モニタリングや個別化された治療調整が可能となっています。これらの技術革新の総体として、高リスク患者の転帰を改善するだけでなく、動脈硬化の診断、モニタリング、およびその臨床的継続全体にわたる管理方法を再定義しています。

どのような外的要因が治療開発の方向性を導いているのか？

科学的進歩にとどまらず、医療政策、規制の枠組み、経済格差、一般市民の意識向上キャンペーンなどの外的要因が、アテローム性動脈治療市場の形成に極めて重要な役割を果たしています。心血管疾患の世界の負担を軽減することを目的とした政府主導のイニシアチブは、特に急速な都市化とライフスタイルの変化を経験している地域において、より広範なスクリーニングプログラムと予防療法への資金提供をもたらしています。規制機関は、標準的な治療に反応しない高リスクのアテローム性動脈硬化症患者に対応する画期的な治療法の承認を迅速に進め始めています。同時に、製薬企業は高い市場ポテンシャルとアンメットニーズを背景に、新規化合物の開発に積極的な投資を行っています。医療制度は、単発的な治療よりも早期介入と長期的な疾患管理にインセンティブを与えるバリューベースのケアモデルをますます支持するようになっています。このようなモデルは、コレステロールを低下させるだけでなく、心血管イベントや死亡率を低下させる治療薬の採用を促進します。さらに、社会経済的格差は治療へのアクセスに影響を与え続けており、多くの中低所得者層は高度な治療を受ける余裕や一貫したフォローアップ治療を維持するのに苦労しています。このため、毎日の服薬アドヒアランスの負担を軽減する、費用対効果の高いジェネリック製剤や長時間作用型薬剤の開発への関心が高まっています。公的な教育・啓発キャンペーンも、患者の動脈硬化症に対する理解を深め、早期受診を促すことで、診断・治療ソリューションに対する需要を支えています。このような規制、経済、社会的要因の相互作用は、アテローム性動脈硬化治療分野における技術革新のペースと焦点を方向付ける上で重要な役割を果たしています。

アテローム性動脈硬化治療市場の成長を促す要因とは？

アテローム性動脈硬化治療市場の成長は、人口動向、科学の進歩、ヘルスケア提供モデルの進化に根ざしたいくつかの要因によって牽引されています。最も重要な要因の一つは、世界人口の高齢化であり、心血管危険因子の有病率が高くなるため、長期的なアテローム性動脈硬化症管理の需要が高まります。同時に、肥満、2型糖尿病、メタボリックシンドロームなどの生活習慣病が増加し、動脈硬化やそれに関連する合併症の治療を必要とする患者層が拡大しています。薬理ゲノミクスとプレシジョン・メディシンの進歩は、より的を絞った治療介入を可能にし、有効性を高め、副作用を軽減しています。さらに、医療提供者は、遠隔モニタリングや治療アドヒアランスをサポートするデジタルツールの導入を進めており、従来の薬物療法を補完する補助的治療薬の市場を拡大しています。PCSK9阻害剤、CETP阻害剤、抗炎症剤などの新規薬剤クラスが参入したことで、特に第一選択薬に抵抗性を示す患者に対する治療選択肢がさらに広がっています。支払者や保険会社は、早期かつ積極的な治療が長期的な医療費の削減に費用対効果があることを認識し始めており、先進的な治療に対するより有利な償還政策につながっています。さらに、現在進行中の臨床試験と規制当局の承認により、新たなパイプライン候補が安定したペースで市場に投入され、技術革新の勢いが増しています。生活習慣の管理、診断、薬物介入を含む全人的な心血管治療へのシフトは、マルチモーダルな治療アプローチへの需要を強化しています。その結果、アテローム性動脈硬化治療市場は、臨床ニーズ、技術進化、戦略的ヘルスケアプランニングの組み合わせにより、市場規模が拡大するだけでなく、その範囲も多様化しています。

セグメント

製品（アテローム性動脈硬化症治療用低分子製剤、アテローム性動脈硬化症治療用生物製剤）

調査対象企業の例（計43社）

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc（GSK）
  • Ionis Pharmaceuticals, Inc.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Co.
  • Teijin Pharma Limited
  • Zai Lab Limited

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36221

Global Atherosclerosis Therapeutics Market to Reach US$13.7 Billion by 2030

The global market for Atherosclerosis Therapeutics estimated at US$11.1 Billion in the year 2024, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Atherosclerosis Small Molecules, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Atherosclerosis Biologics segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 6.7% CAGR

The Atherosclerosis Therapeutics market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Atherosclerosis Therapeutics Market - Key Trends & Drivers Summarized

Why Is Atherosclerosis Still a Global Health Crisis Despite Medical Advances?

Atherosclerosis, characterized by the progressive buildup of plaque in arterial walls, remains one of the leading contributors to cardiovascular diseases worldwide. Despite decades of research and the availability of effective therapeutic interventions, it continues to claim millions of lives annually due to heart attacks, strokes, and peripheral arterial disease. This persistent prevalence is partly due to lifestyle factors such as unhealthy diets, sedentary behavior, smoking, and increasing stress levels that collectively elevate the risk of plaque formation. Furthermore, atherosclerosis often develops silently over decades before manifesting in acute cardiovascular events, which makes early detection and intervention particularly challenging. Populations in both high-income and developing countries are increasingly affected as globalization introduces western dietary habits and urbanization contributes to reduced physical activity. Compounding this issue is the rise in coexisting conditions such as diabetes, hypertension, and obesity, all of which are significant accelerators of atherosclerotic progression. Moreover, demographic shifts, especially the global increase in aging populations, have resulted in a growing patient base at risk of or already suffering from atherosclerosis-related complications. Although statins and other lipid-lowering agents have proven effective in managing cholesterol levels, they are often underutilized or insufficient for certain high-risk populations. Patient adherence, limited access to healthcare, and asymptomatic progression also hinder effective disease control. These multifaceted challenges emphasize why atherosclerosis remains an urgent global health concern and highlight the need for more sophisticated, accessible, and personalized therapeutic approaches.

How Is Innovation Reshaping the Landscape of Atherosclerosis Treatment?

The therapeutic landscape for atherosclerosis is undergoing significant transformation, fueled by advancements in biotechnology, precision medicine, and molecular research. Traditional therapies, such as statins and antiplatelet drugs, continue to form the cornerstone of treatment; however, new approaches are emerging that go beyond lipid management to address the underlying inflammatory and immune pathways driving plaque buildup. Monoclonal antibodies, such as PCSK9 inhibitors, have introduced a new era of lipid-lowering therapies that can achieve cholesterol reductions previously unattainable through conventional drugs. These biologics are particularly useful for patients with familial hypercholesterolemia or those who are statin-intolerant. Gene-editing technologies, including CRISPR, are also being explored to modify genes associated with lipid metabolism, potentially offering long-term protection against atherosclerosis. Another area of growth is RNA-based therapeutics, which can silence specific genetic targets involved in lipid synthesis or inflammation. Imaging technologies, such as intravascular ultrasound and optical coherence tomography, are now being integrated with treatment strategies to monitor plaque characteristics and assess therapeutic responses in real time. Drug-eluting stents and vascular scaffolds have evolved in both safety and efficacy, providing localized therapy that complements systemic medication. Additionally, the use of digital health tools and wearable devices is allowing for continuous cardiovascular monitoring and personalized treatment adjustments. Collectively, these innovations are not only improving outcomes for high-risk patients but also redefining how atherosclerosis is diagnosed, monitored, and managed across its entire clinical continuum.

What External Forces Are Steering the Direction of Therapeutic Development?

Beyond the scientific advancements, external factors such as healthcare policy, regulatory frameworks, economic disparities, and public awareness campaigns are playing pivotal roles in shaping the atherosclerosis therapeutics market. Government-led initiatives aimed at reducing the global burden of cardiovascular disease are resulting in broader screening programs and funding for preventive therapies, particularly in regions experiencing rapid urbanization and lifestyle shifts. Regulatory bodies are beginning to fast-track approvals for breakthrough therapies addressing high-risk atherosclerosis patients who fail to respond to standard treatments. At the same time, pharmaceutical companies are investing more aggressively in developing novel compounds, driven by the high market potential and unmet clinical needs. Health systems are increasingly favoring value-based care models, which incentivize early intervention and long-term disease management over episodic treatment. These models promote the adoption of therapeutics that not only lower cholesterol but also demonstrate reductions in cardiovascular events and mortality. Furthermore, socioeconomic disparities continue to influence treatment accessibility, with many low- and middle-income populations struggling to afford advanced therapies or maintain consistent follow-up care. This has led to increased interest in developing cost-effective generic formulations and long-acting drugs that reduce the burden of daily medication adherence. Public education and awareness campaigns are also improving patient understanding of atherosclerosis and encouraging earlier consultations, thereby supporting demand for diagnostic and therapeutic solutions. The interplay of these regulatory, economic, and societal factors is instrumental in directing the pace and focus of innovation within the atherosclerosis therapeutics sector.

What Factors Are Driving Growth in the Atherosclerosis Therapeutics Market?

The growth in the atherosclerosis therapeutics market is driven by several factors rooted in demographic trends, scientific advancement, and evolving healthcare delivery models. One of the most significant drivers is the aging global population, which presents a higher prevalence of cardiovascular risk factors, thereby increasing the demand for long-term atherosclerosis management. Simultaneously, the rising incidence of lifestyle-related conditions such as obesity, type 2 diabetes, and metabolic syndrome is expanding the pool of patients requiring treatment for atherosclerosis or its associated complications. Advances in pharmacogenomics and precision medicine are enabling more targeted therapeutic interventions, boosting efficacy and reducing adverse effects. In addition, healthcare providers are increasingly integrating digital tools that support remote monitoring and treatment adherence, thus expanding the market for supportive therapeutics that complement traditional medications. The entry of novel drug classes, including PCSK9 inhibitors, CETP inhibitors, and anti-inflammatory agents, is further enhancing therapeutic options, especially for patients resistant to first-line treatments. Payers and insurers are beginning to recognize the cost-effectiveness of early and aggressive treatment in reducing long-term healthcare expenditures, leading to more favorable reimbursement policies for advanced therapies. Furthermore, ongoing clinical trials and regulatory approvals are introducing new pipeline candidates into the market at a steady pace, keeping innovation momentum high. The shift toward holistic cardiovascular care, encompassing lifestyle management, diagnostics, and pharmaceutical intervention, is reinforcing the demand for multi-modal therapeutic approaches. As a result, the market for atherosclerosis therapeutics is not only expanding in volume but also diversifying in scope, driven by a combination of clinical need, technological evolution, and strategic healthcare planning.

SCOPE OF STUDY:

The report analyzes the Atherosclerosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Atherosclerosis Small Molecules, Atherosclerosis Biologics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Ionis Pharmaceuticals, Inc.
  • Kowa Company, Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Co.
  • Teijin Pharma Limited
  • Zai Lab Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Atherosclerosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Cardiovascular Diseases Spurs Demand for Atherosclerosis Therapeutics
    • Increased Focus on Preventive Cardiology Drives Development of Early-stage Treatment Options
    • Boom in Aging Populations and Lifestyle-related Risk Factors Expands the Addressable Market
    • Growing Emphasis on Personalized Medicine Throws the Spotlight on Targeted Atherosclerosis Therapies
    • Advances in Lipid-lowering Agents and Anti-inflammatory Drugs Propel Pipeline Innovation
    • Demand for Combination Therapies and Multimodal Treatment Strategies Strengthens Clinical Adoption
    • Here's How Biomarker-driven Approaches Enhance Precision and Treatment Efficacy
    • Wider Integration of AI in Drug Discovery and Trial Design Generates Acceleration in R&D
    • Rising Investment in RNA-based and Gene-editing Platforms Sustains Innovation in Next-gen Therapeutics
    • Expansion of Cardiometabolic Care Models Unlocks New Opportunities for Holistic Treatment Protocols
    • Growing Use of Imaging and Diagnostic Tools Fuels Early Detection and Therapeutic Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Atherosclerosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Atherosclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Atherosclerosis Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Atherosclerosis Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Atherosclerosis Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Atherosclerosis Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Atherosclerosis Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Atherosclerosis Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • JAPAN
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • CHINA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • EUROPE
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Atherosclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • FRANCE
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • GERMANY
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • INDIA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Atherosclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Atherosclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
  • AFRICA
    • Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030

IV. COMPETITION